NASDAQ:ACHNAchillion Pharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Achillion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$6.76MA: $6.76▼$6.7652-Week Range N/AVolumeN/AAverage Volume8.44 million shsMarket Capitalization$946.72 millionP/E RatioN/ADividend YieldN/ABeta1.59 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingAchillion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.30, Achillion Pharmaceuticals has a potential upside of ∞ from its current price of $0.00.Amount of Analyst CoverageAchillion Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesAchillion Pharmaceuticals has received 492 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAchillion Pharmaceuticals has received 445 “underperform” votes. (Add your “underperform” vote.)Community SentimentAchillion Pharmaceuticals has received 52.51% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote “Outperform” if you believe ACHN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAchillion Pharmaceuticals does not currently pay a dividend.Dividend GrowthAchillion Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Achillion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.58% of the stock of Achillion Pharmaceuticals is held by insiders.Percentage Held by Institutions79.42% of the stock of Achillion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Achillion Pharmaceuticals are expected to decrease in the coming year, from ($0.59) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achillion Pharmaceuticals is -12.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achillion Pharmaceuticals is -12.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.32 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ACHN Previous Symbol CUSIP00448Q20 CIK1070336 Webwww.achillion.com Phone203-624-7000Debt Debt-to-Equity Ratio0.01 Current Ratio8.96 Quick Ratio8.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($0.51) Net Income$-70,270,000.00 Net MarginsN/A Return on Equity-30.95% Return on Assets-29.09%Miscellaneous Employees56 Outstanding Shares140,047,000Market Cap$946.72 million Next Earnings DateN/A OptionableOptionable Receive ACHN News and Ratings via Email Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter. Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Achillion Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Achillion Pharmaceuticals. How were Achillion Pharmaceuticals' earnings last quarter? Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) issued its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.02. View Achillion Pharmaceuticals' earnings history. What price target have analysts set for ACHN? 2 brokers have issued 12-month target prices for Achillion Pharmaceuticals' stock. Their forecasts range from $6.30 to $6.30. On average, they anticipate Achillion Pharmaceuticals' share price to reach $6.30 in the next year. View analysts' price targets for Achillion Pharmaceuticals. Has Achillion Pharmaceuticals been receiving favorable news coverage? Media headlines about ACHN stock have trended somewhat negative recently, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAchillion Pharmaceuticals. Who are some of Achillion Pharmaceuticals' key competitors? Some companies that are related to Achillion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors. What other stocks do shareholders of Achillion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHK), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Iconix Brand Group (ICON), ACADIA Pharmaceuticals (ACAD), Celldex Therapeutics (CLDX) and Edap Tms (EDAP). Who are Achillion Pharmaceuticals' key executives? Achillion Pharmaceuticals' management team includes the following people: Mr. Joseph Truitt, Pres, CEO & Director (Age 54)Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 64)Mr. Brian R. Di Donato, CFO, SVP & Treasurer (Age 52)Mr. Paul Firuta, Exec. VP & COO (Age 53)Dr. Kevin P. Malobisky, Sr. VP of Regulatory Affairs, Quality & Compliance What is Achillion Pharmaceuticals' stock symbol? Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN." How big of a company is Achillion Pharmaceuticals? Achillion Pharmaceuticals has a market capitalization of $0.00. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Achillion Pharmaceuticals employs 56 workers across the globe. What is Achillion Pharmaceuticals' official website? The official website for Achillion Pharmaceuticals is www.achillion.com. How can I contact Achillion Pharmaceuticals? Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000. This page was last updated on 6/6/2020 by MarketBeat.com Staff
